Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Meta Expands AI Training With Employee Activity Tracking Tools 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
COLUMBIA, Md., March 31, 2017 -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), announced today the passing of one of its Board Members, Yves Huwyler.
"It deeply saddens me to announce the untimely loss of a dear friend and most valued Partner and Director Yves Huwyler, who died at the age of 44, after a long struggle with an aggressive illness,” said Peter Friedli, Chairman and Co-founder of Osiris Therapeutics, Inc. “Your smartness, your challenging views, your wise approaches, and your hard work were key in bringing Osiris to where it is and will be missed. Your sons can be so proud of you and everything you have achieved. We at Osiris thank you whole-heartedly for your contribution and wisdom. We will miss you and always remember your kind personality. On behalf of the entire organization, I extend our deepest sympathies, strength, and courage to your family and all those who were close to you in this time of sorrow.”
Mr. Huwyler led the Nominating and Compensation Committees of Osiris’ Board of Directors since 2015, and he was a member of the Board’s Audit Committee. Mr. Huwyler had over 18 years of experience in private equity investing in various sectors and at all stages, and as a member of the Board of Directors he actively contributed to our Company’s success. All members of the Board and Osiris’ management team join Mr. Friedli in expressing their deepest condolences.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix®, BIO4®, and Cartiform®. Osiris, Grafix, Cartiform, and Stravix are registered trademarks of Osiris Therapeutics, Inc., and BIO4 is a registered trademark of Howmedica Osteonics Corp. More information can be found on the Company's website, www.Osiris.com. (OSIR-G)
For additional information, please contact: Diane Savoie Osiris Therapeutics, Inc. (443) 545-1834 [email protected]
